SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

AJ2-30

Item No. 40667



CAS Registry No.:	2700322-79-6
Formal Name:	9-ethyl-N-(1-methyl-1H-benzimidazol-2-yl)-9H-carbazole-3-methanamin
MF:	$C_{23}H_{22}N_4$
FW:	354.5
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AJ2-30 is supplied as a solid. A stock solution may be made by dissolving the AJ2-30 in the solvent of choice, which should be purged with an inert gas. AJ2-30 is sparingly soluble (1-10 mg/ml) in DMSO.

Description

AJ2-30 is an inhibitor of the endolysosome transporter solute carrier family 15 member A4 (SLC15A4).[1] It is selective for SLC15A4 over SLC15A3 at 5 µM. AJ2-30 reduces increases in IFN-α levels induced by the toll-like receptor 9 (TLR9) agonist CPG-2216 in primary human plasmacytoid dendritic cells (IC_{50} = 1.8 µM). It also inhibits NOD2 signaling mediated by the NOD2 ligand muramyl dipeptide (MDP; Item No. 30866) in a reporter assay using A549 cells expressing membrane-localized SLC15A4 (IC_{50} = 2.6 µM). AJ2-30 reduces increases in IFN-α and IL-6 induced by the TLR9 agonist CPG-2006 or the TLR7 agonist R-837 (imiquimod; Item No. 14956) in peripheral blood mononuclear cells (PBMCs) isolated from patients with systemic lupus erythematosus (SLE). It reduces IFN-α, IFN-β, and IFN-γ production induced by a CPG-2216-DOTAP complex in mice when administered at a dose of 50 mg/kg.

Reference

1. Chiu, T.Y., Lazar, D.C., Wang, W.W., *et al.* Chemoproteomic development of SLC15A4 inhibitors with anti-inflammatory activity. *Nat. Chem. Biol.* Online ahead of print, (2024).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM